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INTRODUCTION
According to the International Agency for Research on Cancer 
(Lyon, France), more than 10 million patients with malignant 
neoplasms were registered in the world in 2000, and the num-
ber of new cases is projected to reach 16 million in 2020 [1]. 
The problem of leukemia is one of the most urgent. Leukemia 
is about 8% of the total number of malignant tumors, and are 
among the six most common cancers. Every 3 minutes a new 
case of cancer is registered in the USA, and every 9 minutes 
one of the patients dies [2]. Up to 8 thousand  new cases of 
oncohematological diseases are diagnosed annually in Ukraine. 
The index of morbidity per 100 thousand population at lym-
phogranulomatosis is 2,5; at MM – 1,6; at leukemia – 8,1 [3]. 
According to official data, the incidence of hemoblastosis in 
Ukraine during the last 20 years has increased from 14,7 (in 
1991) to 18.9 per 100 thousand population (2014). The absolute 
number of newly diagnosed patients also increased [4, 5, 6]. The 
end of oncohematological diseases is often unfavorable. Timely 
diagnosis provides 2/3 of success in overcoming illness. The 
situation with the treatment of acute leukemia in adults remains 
unsatisfactory. The frequency of remissions abroad – 50–80%, 
in Ukraine it does not exceed 20-40% [7]. The using of inte-
grated therapies allowed prolong the patients’ lives with AL in 
remission, up to 3-5 years in 35–40% of cases and to remove the 
terms of patients’ disability with chronic blood and lymphoid 
tissue diseases [8]. At the same time, the survival prognosis of 
patients with AL became worst with infectious complications 
(IC), among them the leading role belongs to pneumonia [8]. 
It is proved that the course of AL is characterized by a high 
incidence of IC, which pneumonia is the main one. It occurs 
in 53% of hospitalized in the hematological department [9]. 
Mortality in such cases is quite high and makes up 28% [8]. 
Progressive increase of pneumonia poor outcome is determined 
even modern antibacterial drugs using. The mortality level of 
patients with AL and pneumonia reaches to 40% in the intensive 
care units [10].
DETERMINATION OF POOR OUTCOME PROGNOSIS 
IN PATIENT WITH ACUTE LEUCEMIA WHICH WAS COMPLICATED 
BY PNEUMONIA
CZYNNIKI RYZYKA ZŁEGO ROKOWANIA U PACJENTÓW Z OSTRĄ 
BIAŁACZKĄ POWIKŁANĄ ZAPALENIEM PŁUC
Inna S. Borisova, Dmitry O. Stepansky
SE «DNIPROPETROVSK MEDICAL ACADEMY OF HEALTH MINISTRY OF UKRAINE», DNIPRO, UKRAINE
ABSTRACT
Introduction: At the present stage, the medicine development is based on the principles of evidence-based medicine, which requires using of statistical methods and forecasting. 
Using statistical analysis and possibilities and mathematical forecasting emphasizes the probability of obtained data in scientific medical research. Identifying the factors that 
determine the survival of patients with acute leukemia and pneumonia causes the conduct of this study.
The aim: To create a mathematical model of poor outcome prognosis in patients with acute leukemia, which was complicated by pneumonia, to determine the treatment place 
and timely optimize the treatment.
Materials and methods: An electronic database of formalized disease history of 360 patients with acute leukemia and pneumonia was created. The data base contained data 
of objective survey and additional research methods. In our study we used non-parametric dispersion analysis of Kraskele-Wallis, correlation analysis with the calculation of 
Spierman’s rank correlation coefficients, simple and multiple logistic regression analysis with the calculation of the odds ratio; ROC analysis. The significance level p <0,05 was 
considered statistically significant.
Results: It was determined that with the onset of the lethal outcome of patients with pneumonia, developed on the background of acute leukemia, the indicators of leukocytes, 
lymphocytes, neutrophils, platelets, erythrocytes, hemoglobin and immunity indexes (B(CD19+), T(CD4+), CD4+/CD8+, IgG). According to the results of our study, a mathematical 
model of prediction poor outcome in patients with acute leukemia, which was complicated by pneumonia, was created: PPO=exp(-10,317+0,410* В(CD19+) -2,149* IgG)/
[1+exp(-10,317+0,410* В(CD19+) -2,149* IgG)].
Conclusion: Using in clinical practice the proposed mathematical model of prediction poor outcome in patients with acute leukemia, which was complicated by pneumonia, 
will allow determining the treatment place and timely optimizing the treatment program.
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At the present stage, the medicine development is based 
on the principles of evidence-based medicine, which re-
quires using of statistical methods and forecasting. Using 
statistical analysis and possibilities and mathematical 
forecasting emphasizes the probability of obtained data 
in scientific medical research. Identifying the factors that 
determine the survival of patients with AL and pneumonia 
causes the conduct of this study.
THE AIM
To create a mathematical model for determine the forecast 
of pneumonia poor outcome in patients with acute leuke-
mia in order to define patient’s treatment place and timely 
optimize the treatment. 
MATERIALS AND METHODS
The study was conducted in the hematological center of 
“City Multidisciplinary Clinical Hospital №4”, Dnipro 
(2012–2015 yrs). 360 patients with pneumonia developed 
on a background of AL were investigated. The patients 
were divided according to the American Thoracic Society 
recommendations 2007 [15]: the 1st group consisted of 109 
patients with mild and moderate severity of pneumonia, 
which developed shortly after hospitalization; the 2nd group 
consisted of 65 patients with mild and moderate severity 
of pneumonia, which developed at any time, all patients 
have risk factors; the 3rd group – 53 patients with severe 
pneumonia, which developed shortly after hospitaliza-
tion, all patients have risk factors and patients with late 
pneumonia with severe course. In addition, we identified 
4th group – patients with pneumonia poor outcome. This 
group consisted of 133 patients. 
Diagnosis of pneumonia and CL form were performed in 
accordance with generally accepted clinical, laboratory and 
morpho-immunohistochemical studies [1, 2, 7, 8, 9, 17].
General clinical methods included data of anamnesis, 
including anamnesis of oncohematological disease (form, 
stage of the disease, its first signs, duration, presence of 
B-symptoms, enlargement of liver, spleen, lymph nodes 
(LV), number of chemotherapy courses (CT), which pre-
ceded the IC of the broncho-pulmonary system, the pres-
ence of concomitant pathology, anamnesis of pneumonia 
(communiyu aquared pneumonia, nosocomial pneumonia 
(early, late)); the beginning, the presence of generally ac-
cepted clinical signs; data of pneumonia clinical picture and 
complaints (the presence, number and nature of sputum, 
the presence, number and type of dyspnea, the time when 
complaints began, temperature reaction dynamics); data 
of patient’s physical examination, including in dynamics 
(data of percussion, auscultation); results of laboratory 
methods of research in dynamics ( complete blood count, 
biochemical blood test); general sputum analysis; chest 
X-Ray in two projections and / or computed tomography 
(CT) of the lungs (if necessary in dynamics); to determine 
the probable pathogens of pneumonia – bacterioscopic and 
microbiological study of sputum and fluid of broncho-alve-
olar lavage (BAL); fibrobranchoscopy to obtain BAL fluid; 
immuno-enzymes study - to determine the parameters of 
cellular and humoral immunity. 
All quantitative and qualitative (nominal) indices were 
entered into the electronic database of formalized disease 
histories like “object-sign” table. These data gradually and 
statistically processed using descriptive and analytical 
biostatistics methods implemented in software packages 
Table I. Odds ratio clinical and laboratory parameters influence on mortality, depending on their threshold predictive value of the studied patients
Indexes 
(1 – yes, 0 – no) OR 95% CI
Patients proportion, (%)
p
Alive Dead
Neutrophils ≤1,24 109/l 10,20 5,52 - 18,83 7,05  43,61  <0,001
Pulse >92 per min. 17,31 9,90 - 30,26 10,57  67,18  <0,001
Leukocytes ≤3,7 109/l 60,00 7,60 - 473,85 28,57  96,0 % <0,001
Lymphocytes ≤18,9 % 9,90 4,51 - 21,76 18,75  69,57  <0,001
B CD19≤0,467 g/l 68,85 4,0 - 1185,95 37,14  100,0  <0,001
T CD19+ >58,13 % 85,79 18,06 - 407,47 14,46  93,55  <0,001
СD4 ≤ 21,77 % 285,0 32,41 - 2506,38 78,4 21,6 <0,001
СD4 ≤0,71 g/l 28,80 6,14 - 134,98 6,25  95,0  <0,001
СD4/СD8 ≤1,05 437,0 46,23 - 4130,90 4,17  95,0  <0,001
Ig G ≤8,21 g/l 43,54 5,51 - 344,13 30,38  95,0  <0,001
FA ≤22% 14,44 4,19 - 49,75 8,70  57,89  <0,001
Creatinine >94 mkmol/l 3,84 2,44 - 6,03 32,30  64,66  <0,001
HB ≤90 g/l 6,02 3,72 - 9,73 33,48  75,19  <0,001
Erythrocytes ≤1,97 1012/l 36,67 19,21 - 70,00 6,61  72,18  <0,001
ESR >33 mm/h 4,63 2,92 - 7,34 31,86  68,42  <0,001
Platelets≤60 109/l 8,50 5,15 - 14,03 15,49  60,90  <0,001
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“STATISTICA 6.1” (StatSoftInc., Serial No. AGAR909E-
415822FA); Microsoft Excel (Office Home Business 
2KB4Y-6H9DB-BM47K-749PV-PG3KT). Median (Me), 
as a measure of the central trend, was used to describe 
the quantitative indices; interquartile scale ((25%, 75%) 
–  25 and 75 percentiles respectively, Q1 and Q3 –  first 
and third quartiles) to describe the sings variation., The 
nonparametric dispersion analysis of Kraskele-Wallis and 
a correlation analysis with the calculation of the Spirman 
rank correlation coefficients (ρ) were used in statistical 
analysis of study results. Multiple comparisons were made 
with Bonferon and Hill. The statistically significant level 
was p <0,05 (5%) [10].
RESULTS
Correlation between mortality and clinical, anamnestic, 
laboratory parameters shows the existence of probable 
connection between poor outcome forecast and 36 quan-
titative and qualitative sings. 
The indicators with statistically significant, average and 
high correlation coefficients (0,29 <ρ <1,0) were selected 
for a more detailed analysis of which factors affect on poor 
outcome. The next step was - to analyze the effect of quan-
titative and nominal indicators on the mortality of patients 
with pneumonia and AL using a simple logistic regression 
analysis. Cutoff points were identified using the ROC 
analysis – the critical values of the clinical and laboratory 
results, which achieved the maximum predictive value of 
the indicator to predict the probability of pneumonia poor 
outcome [18].
Leukocytes, lymphocytes, neutrophils, platelets, eryth-
rocytes, hemoglobin, B (CD19 +) (g / l), CD4 + (%), 
immunoregulatory index (CD4 + / CD8 +) and IgG (g / l) 
showed the most prognostic ability to predict pneumonia 
lethal outcome in patients with AL (Tab. I). 
The relationship between the signs “died” or “survived” 
analyzed using a logistic regression model with a step-by-
step algorithm predictors inclusion [13, 14]. The logistic 
equation used as the basis for developing the prediction 
model: y = exp (b0 + b1 * x1 + ... + bn * xn) / [1 + exp (b0 
+ b1 * x1 + ... + bn * xn)] (1) , where: y – the result (in our 
study – the prediction of pneumonia poor outcome (PPO); 
b0 –  the free part of the regression equation; b1 – bn - re-
gression coefficients; x1-xn – predictor variables.
If the calculated probability of pneumonia poor outcome 
will be less than 0,5, we can assume that the event will not 
occur (the patient will not die); if probability more than 
0,5 – the poor outcome of pneumonia is reliable.
We received the logistic regression equation parameters 
represented as a result of a step-by-step inclusion of inde-
pendent variables. It’s presented in tab. II (only meaningful 
factors are included in the table). For quantitative predic-
tors, the index entered in the equation in units values, for 
binary 1 – factor is presented, 0 – is not. 
We calculated the regression coefficient β during logistic 
regression analysis, its error, and χ2 Wald statistics. Coeffi-
cient β describes the change of the mortality risk due to risk 
factor change for the one unit. We estimated the predictive 
precision of the logistic regression equation using the Hi-
square (χ2); percentage of concordant - the proportion of 
correctly reclassified observations (the closer this figure 
to 100%, the higher model quality); Hosmer-Lemeshov’s 
consent test and ROC-analysis. The evaluation of logistic 
regression equations using Xi-square (χ2) showed their 
precision, it was determined the statistically significant 
level χ2 (p <0,001). The proportion of correct prediction 
for patients with AL membership of a particular group 
Table II. Forecast of pneumonia poor outcome in patients AL according to logistic regression analysis
Prognostic Variables Regression coefficient β
Standard error of 
coefficient β Wald’s χ
2 Wald’s p-value χ2
Free member of the equation -10,317
T CD19+ % (х1) 0,410 0,162 6,429 0,011
Ig G (х2) -2,149 0,944 5,189 0,023
Logistic equation y=exp(-10,317+0,410*x1-2,149*x2)/
[1+exp(-10,317+0,410*x1-2,149*x2)]
Хі- square χ2= 65,37 (p<0,001)
Percentage of concordance 93,67 %
Hosmer-Lemeshov Test 0,127 (р=0,999)
Forecasting operating characteristics according to ROC analysis 
Sensitivity, % 100,0
Specificity, % 90,48
AUC 0,991
95 % CІ AUC 0,938 - 1,000
р <0,001
Qualitative assessment of the model excellent 
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(survivor, died) was 93,67%. This concordance indicator 
shows a high degree of consistency in the real distribution 
of mortalities and distribution based on the logistic re-
gression equation. Overall consensus actual and estimated 
data based on Hosmer- Lemeshov test showed significant 
match, because p > 0,05 was for all equations. That allows 
us to take zero hypothesis regarding the consistency of the 
theoretical and actual results of the disease. 
According to the ROC curve’s shape and the area under 
it (AUC), we estimated the predictive precision of logis-
tic regression equations. The area under the ROC curve 
shows the dependence between the numbers of correctly 
and incorrectly classified pneumonia poor outcome cases. 
The closer curve to the upper left corner and the bigger the 
area under the curve, the better its discriminatory power. 
When the AUC is 0.9 - 1, the model’s quality is considered 
“exellent”; 0,8 – 0,9 – “very good”; 0,7 – 0,8 – “good”; 0,6 – 
0,7 – “average”; 0,5 – 0,6 – “unsatisfactory”; the value less 
than 0,5 indicates the model’s unsuitable [18,19].
Thus, it is determined that the proposed prognostic 
model – the logistic regression equation has excellent 
operational characteristics – sensitivity 100,0%, specific-
ity 90,48%, area under the ROC curve – 0,991 (p <0.001) 
(Table II, Fig. 1).
The constructed logistic models were acceptable relying 
on the criterion χ2; the percentage of concordation, the 
Hosmer-Lemeshov test and the ROC-analysis. The pre-
dicted values (y) in regression models will be always in 
ranges from 0 (survived) to 1 (died), regardless of regres-
sion coefficients or x-values. When calculated probability 
is less than 0,5, we can supposed that event will not occur 
(the patient will not die); otherwise (probability more than 
0,5) – the pneumonia poor outcome will be [19].
We propose a detailed scale for predicting the pneumonia 
poor outcome (PPO) in patients with AL based on all of 
the above calculations:
- up to 0,21 - very low probability of PPO (P <5,24%);
- 0,22 - 0,42 - low probability of PPO (5,24% ≤ R <25,08%);
-  0,43 - 0,55 - average probability of PPO (25,08% ≤ R 
<50,50%);
-  0,56 – 0,81 - high probability of PPO (50,50% ≤ R ≤ 
90,45%);
-  higher than 0.82 - very high probability of PPO (P> 
90,45%).
DISCUSSION
Despite the presence of a sufficiently large number of 
prognostic and diagnostic scales, which are certainly use-
ful for a physician, which solves the issue of choosing the 
treatment place, diagnosis, the severity of pneumonia, we 
can’t consider this issue to be finally resolved, especially for 
certain categories of patients, in particular for patients with 
AL and pneumonia. Earlier the determination of the fore-
cast mortality based on the analysis of leading symptoms 
and syndromes, but at present time it is possible to use the 
mathematical apparatus [17]. Quantitative analysis pro-
vides an opportunity to determine prognostic evaluation 
criteria in numerical terms enriching and supporting the 
meaningful analysis, making it more evidence, excluding 
contradictory methods [17].
The study identified the factors predicting pneumonia 
poor outcome in patients with pneumonia, developed on 
the background of AL. The study proved that the predic-
tors of the poor outcome were: leukocytes, lymphocytes, 
neutrophils, platelets, erythrocytes, hemoglobin, as well 
as immunity parameters: B (CD19 +) (G / L), CD4 + (%), 
immunoregulatory index (CD4 + / CD8 +) and IgG (g / l). 
The logistical equation included two of the most influential 
indicators - B CD19 + (G / L) and IgG (g / l). It is known 
that the main effector cells-killers are T-lymphocytes. They 
provide recognition and destruction of cells that carry 
external antigens, in particular infectious agents [20]. The 
number of these cells is usually lowered in patients with 
acute leukemia. The function of B-lymphocytes with the 
phenotype B (CD19 +) is the formation of complexes with 
antigenic receptors of B-lymphocytes and a decrease in the 
threshold of sensitivity of these receptors that stimulate the 
functional activity of T-killers [20]. Also, this phenotype, 
in terms of its quantitative reduction, characterizes the 
redistribution of lymphocytes to the inflammatory site. 
Therefore, it is clear that the quantitative decrease of B 
(CD19 +) is defined as a predictor of the poor outcome of 
such a severe IC, as pneumonia in patients with AL. The 
obtained data coincide with the data of other researchers, 
which determined the role of the indicator B (CD19 +) 
for its increase - as a sign of a favorable forecast; for a de-
crease - as a sign of an unfavorable prognosis in patients 
with MM [21].
Using in clinical practice the obtained equation will allow 
to predict the pneumonia poor outcome in patient with 
chronic leukemia with a small number of parameters that 
Fig.1. Operational characteristics of the forecasting pneumonia poor outcome 
logistic regression model in patients with AL according to ROC analysis.
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are available today in clinics with hematological profile. De-
termination the probability of PPO in patients with AL has 
a fundamental value for timely choice the treatment tactics:
-  0,21 – 0,42 –  low probability of PPO – it is possible to 
treat pneumonia in outpatient settings or in a therapy, 
hematologist consultation is necessary;
-  0,43 – 0,55 – average probability of PPO – treatment 
in therapy, hematologist consultation in dynamics of 
treatment;
-  0,56 – 0,81 –  high probability of PPO –  treatment in 
a hematological hospital, determination of immunity 
parameters in dynamics, consideration necessity of ABT 
modification;
-  more than 0,82 –  very high probability of PPO –  treatment 
in the department of intensive care, optimization of ABT.
CONCLUSIONS
1.  Results of our study prove that the forecast of pneumo-
nia poor outcome in patients with acute leukemia is 
associated with: leukocytes, lymphocytes, neutrophils, 
platelets, erythrocytes, hemoglobin and immunity: B 
(CD19+) (G/L), T (CD4+) (%), immunoregulatory 
index (CD4+/СD8+) and IgG (g/l).
2.  Mathematical modeling is a modern, necessary instru-
ment in medical practice. A mathematical model for 
predicting the pneumonia poor outcome in patients 
with acute leukemia was created in our study: PPO = 
exp (-0.073-0.994 * (leukocytes) + 4.842 * (P. aerogi-
nosa)) / [1 + exp (-0.073-0.994 * (leukocytes) + 4.842 
* (R. aeroginosa)].
3.  Using in clinical practice the proposed mathematical 
model of prediction pneumonia poor outcome in pa-
tients with acute leukemia will allow determining the 
treatment place and timely optimizing the treatment 
program. If the result of equality is 0,21 – 0,42 – it is 
possible to treat pneumonia in outpatient settings or in 
a therapy, hematologist consultation is necessary; 0,43 – 
0,55 – treatment in therapy, hematologist consultation 
in dynamics of treatment; 0,56 – 0,81 – treatment in a 
hematological hospital, determination of immunity pa-
rameters in dynamics, consideration necessity of ABT 
modification; if result more than 0,82 –  treatment in 
the department of intensive care, optimization of ABT.
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